Skip to main content
Premium Trial:

Request an Annual Quote

Emkjer Set to Make Mark on Accelrys

Premium

Mark Emkjer wants to put Accelrys through boot camp. “I think we need more discipline. I think we absolutely need to obsess about our clients,” he says, still brand-new in his position as president of the Pharmacopeia subsidiary. Emkjer, who replaces former Accelrys COO Mike Stapleton, says this client-centered strategy will bring the company to its goal of $200 million in revenues.

Emkjer is a 23-year veteran of the healthcare industry, most recently as president and COO of Sunquest Information Systems.

He is confident that Accelrys will soon meet its goal of profitability. “I’m not a scientist, but I am a proven software executive, and the processes are all identical. It’s obsess about your client, it’s deliver on time. … In this space, historically, many companies have had a focus purely on the science without looking at the [business] metrics, and unfortunately I think that era is over with,” he says.

In line with fashionably sober post-Enron business mores, Emkjer notes, “one of the things I’m going to focus on is making sure that the disciplines are here to be profitable.”

Emkjer boasts an impressive track record of turning around his previous employer. When he joined Sunquest in 1999, the company’s stock was valued at $8 and it was earning 48 cents per share. When Sunquest was acquired in 2001, the stock price had tripled to $24 and earnings increased to $1.39 per share. And the company’s employee turnover rate decreased from 25 percent to 7.8 percent.

As a newcomer in the informatics space, however, Emkjer certainly will be heavily scrutinized. Some observers are skeptical of his chances for success.

“Mike [Stapleton] was a guy who understood the software business pretty well,” says Stefan Loren, an analyst with Legg Mason who covers Accelrys. “The software business, when you’re selling to a pharmaceutical company, is very different than the software business when you’re selling to healthcare companies.”

However, says Loren, experience in healthcare is better than some alternatives: “We’re not getting somebody who was selling peanuts or anything.”

— Bernadette Toner

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.